From:  Real-life effectiveness of mepolizumab on remission and chronic rhinosinusitis with nasal polyps in severe eosinophilic asthma

 Pre- and post-treatment comparison of clinical and laboratory findings in all patients.

Parameters N = 99Pre-treatmentMonth 1Month 4Year 1p value
FEV168 (51–80)/80 (61.5–88)83.5 (68.7–92)< 0.001
FEV1 (L)2.07 (1.61–2.48)/2.17 (1.63–2.2)2.23 (1.67–2.7)/
Number of emergency service visits4 (2–5)//1 (0–2)< 0.001
OCS use (mg)12 (8–16)0 (0–4)/0 (0–8)< 0.001
Frequency of attacks4 (2–6)//1 (0–1.5)< 0.001
Eosinophil count885 (522–1,192)70 (40–130)80 (40–140)90 (50–197)< 0.001
Eosinophil percentage9.35 (5.67–13.0)0.7 (0.40–1.50)0.9 (0.42–1.60)1.1 (0.7–2.2)< 0.001
IgE level160 (67.8–390)139.5 (68–243)123 (61–243)131 (56–276)0.173
ECP65.4 (40–150)31 (23–60)24.75 (14.6–46.3)28.2 (17–45.7)< 0.001
ACT14 (12–17)20 (18–23)23 (21–24)24 (18–25)< 0.001
ACQ1.4 (1.1–1.8)0.9 (0.6–1.1)0.7 (0.4–0.9)0.9 (0.5–1.1)< 0.001
NPS5 (6–3)//2 (4–2)< 0.001
LMS18 (6–23)//9 (4–16)< 0.001
SNOT-2247 (42.5–67)//23 (12–54)< 0.001
Return to article view

FEV1: forced expiratory volume in 1 second; OCS: oral corticosteroid; IgE: immunoglobulin E; ECP: eosinophil cationic protein; ACT: asthma control test; ACQ: asthma control questionnaire; NPS: nasal polyp score; LMS: Lund-Mackay CT score; SNOT-22: Sino-Nasal Outcome Test-22. /: indicates data not collected or unavailable for this timepoint. For eosinophil count, eosinophil percentage, IgE level, ECP, ACT, and ACQ, p-values indicate within-group comparisons between baseline and each follow-up timepoint (Week 4, Week 16, and Month 12). For FEV1, FEV1 (L), number of emergency service visits, OCS use (mg), NPS, LMS, and SNOT-22, p-values represent comparisons between baseline and Month 12. Continuous variables are presented as median (interquartile range, IQR).